Geron is a late-stage biopharmaceutical company pursuing discoveries with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science that may alter the underlying drivers of disease. The United States Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat.